Table 3 Treatment of gastric cancer with ZD6126: time course

From: ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer

  

ZD6126 (100 mg kg−1)

 

Control

Day 1

Day 3

Day 5

Tumour weight (g)

0.6±0.3

0.3±0.06

0.2±0.01

0.3±0.02

Tumour volume (mm3)

250.1±75.7

242.6±31.0

167.8±47.3

134.2±34.6

Proliferating cells # of cells/HPF

112.3±7.3

43.7±14.7a

78.4±14.6b

33.0±10.0a

Apoptotic cells # of cells/HPF

0.8±0.3

12.0±6.6b

16.2±7.9c

7.2±3.3b

Microvessel density # of vessels/HPF

32.9±2.7

29.3±2.4

25.7±2.9

22.8±2.6a

Proliferating EC # of cells/HPF

2.5±0.4

1.1±0.3b

1.1±0.18c

1.3±0.3b

Apoptotic EC # of cells/HPF

0.6±0.1

0.7±0.3

1.2±0.3

0.6±0.1

Ratio of apoptotic to proliferating ECs (% control)

0.3

0.6c (57%)

1.1c (67%)

0.8b (68%)

  1. TMK-1 tumours growing in the gastric wall were harvested at 1 day, 3 days and 5 days post-ZD6126 injection. Tissue sections were stained with antibodies against CD31, BrdU and TUNEL to determine MVD, endothelial cell proliferation and endothelial cell apoptosis. Measurements are the mean±the standard error, as determined by counting the positive cells in each of five × 100 high-powered fields (HPF) for three tumours from each treatment or control group. EC=endothelial cell.
  2. aP<0.004.
  3. bP<0.05.
  4. cP<0.01.
Back to article page